TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1685533

Group type: EXPERIMENTAL
Intervention: 0.25% dapiprazole
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1% acetylcholine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 90
Study: 6972401

Group type: EXPERIMENTAL
Intervention: Unmodified ragweed extract (RW)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Glutaraldehyde polymer of ragweed extract (PRW)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 30707225

Group type: EXPERIMENTAL
Intervention: Repeated antenatal betamethasone treatment
Number of subjects: 988

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 988
Study: 29490637

Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 26727697

Group type: EXPERIMENTAL
Intervention: Tonsillectomy combined with drug therapy (Group A)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Drug therapy alone (Group B)
Number of subjects: 98
Study: 24083998

Group type: EXPERIMENTAL
Intervention: Higher CMV serointensity in patients with schizophrenia
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Higher CMV serointensity in patients with bipolar disorder
Number of subjects: 289

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 289
Study: 22469291

Group type: EXPERIMENTAL
Intervention: Up front surgery of the breast tumor followed by systemic therapy
Number of subjects: 516

Group type: COMPARATOR
Intervention: Systemic therapy followed by delayed local treatment of the breast tumor if clinically indicated
Number of subjects: 516
Study: 20413364

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg plus fenofibric acid 135 mg daily for 18 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17507311

Group type: EXPERIMENTAL
Intervention: Enediyne compounds
Number of subjects: 0
Study: 15610940

Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) isradipine 15 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) isradipine 30 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both IR and SR isradipine
Number of subjects: 8
Study: 12137829

Group type: EXPERIMENTAL
Intervention: ProstaLund Feedback Treatment (PLFT)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 154
Study: 10202826

Group type: EXPERIMENTAL
Intervention: NVP + ZDV
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: ddl + ZDV
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: NVP + ddl + ZDV
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Triple combination regimen (NVP + ddl + ZDV)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Virological responders (long-term)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Virological failure
Number of subjects: 29
Study: 7472658

Group type: COMPARATOR
Intervention: Continued exclusive breast-feeding to 6 months (EBF)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Introduction of complementary foods at 4 months, with ad libitum nursing 4-6 months (SF)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Introduction of complementary foods at 4 months, with maintenance of baseline nursing frequency 4-6 months (SF-M)
Number of subjects: 141
Study: 30642252

Group type: EXPERIMENTAL
Intervention: Test-and-Exercise (T&E) programme
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Otago Exercise Programme
Number of subjects: 405

Group type: COMPARATOR
Intervention: Helsana programme (recommendation-booklet and exercise-cards)
Number of subjects: 405
Study: 28503818

Group type: EXPERIMENTAL
Intervention: Lidocaine spray
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lidocaine injection
Number of subjects: 200

Group type: COMPARATOR
Intervention: Lidocaine cream
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 26713003

Group type: EXPERIMENTAL
Intervention: Iguratimod
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 74
Study: 23729929

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 48
Study: 22177021

Group type: EXPERIMENTAL
Intervention: Combined intervention of health education and sexual health services
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Health education only
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Sexual health services only
Number of subjects: 739

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 739
Study: 19699566

Group type: EXPERIMENTAL
Intervention: Minimally invasive direct anterior approach (DA)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Traditional anterolateral approach (AL)
Number of subjects: 33
Study: 17383264

Group type: EXPERIMENTAL
Intervention: Total fat- and saturated fat-modified dietary intervention
Number of subjects: 653

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 653
Study: 15502065

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway Unique (LMA‐U)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Soft Seal laryngeal mask airway (SSLM)
Number of subjects: 90
Study: 11887672

Group type: EXPERIMENTAL
Intervention: System A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: System B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: System C
Number of subjects: 0
Study: 9543326

Group type: EXPERIMENTAL
Intervention: Propentofylline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8165045

Group type: EXPERIMENTAL
Intervention: Human milk (high cholesterol, low phytoestrogen)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Soy milk‐based formula (zero cholesterol, high phytoestrogen)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cow milk‐based formula (low cholesterol, low phytoestrogen)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Modified soy milk‐based formula (low cholesterol, high phytoestrogen)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Modified soy milk‐based formula
Number of subjects: 33
Study: 3243094

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 1.5 g and 1.2 g
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 2 g (single dose)
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 2 g for 10 days
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 1 g
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 2 g
Number of subjects: 683
Study: 31996614

Group type: EXPERIMENTAL
Intervention: High-frequency (HF) training (3 days per week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-frequency (LF) training (1 day per week)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both HF and LF protocols
Number of subjects: 30
Study: 30224019

Group type: EXPERIMENTAL
Intervention: Tacrolimus 2-3 mg daily
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 27330698

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Naproxen 500 mg bid for 3 weeks
Number of subjects: 40
Study: 25907848

Group type: EXPERIMENTAL
Intervention: Intensive remedial teaching using multisensory reading program with greater kinesthetic demands
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Intensive remedial teaching using multisensory reading program with greater visual-spatial demands
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group - wait-list IRD (no treatment)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group - typically developing readers (no treatment)
Number of subjects: 49
Study: 24047126

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirabegron 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20961406

Group type: EXPERIMENTAL
Intervention: Multidisciplinary cognitive behavioural treatment programme (11 sessions over 3 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting list control group (invited for the programme 6 months after the intervention group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multidisciplinary cognitive behavioural treatment programme
Number of subjects: 60
Study: 18242454

Group type: EXPERIMENTAL
Intervention: Xylocaine 1%
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cyclopentolate after Xylocaine
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Phenylephrine after Cyclopentolate
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Phenylephrine after Xylocaine
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cyclopentolate after Phenylephrine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Intracameral mydriatics with cyclopentolate
Number of subjects: 56
Study: 16023336

Group type: EXPERIMENTAL
Intervention: Tubing group (n=140)
Number of subjects: 295

Group type: COMPARATOR
Intervention: No-tubing group (n=155)
Number of subjects: 295
Study: 12826039

Group type: EXPERIMENTAL
Intervention: Docetaxel (T)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequential methotrexate and 5‐fluorouracil (MF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline QoL
Number of subjects: 0
Study: 10806602

Group type: EXPERIMENTAL
Intervention: Sibrafiban with ASA
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sibrafiban alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sibrafiban with heparin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sibrafiban with ASA and heparin
Number of subjects: 24
Study: 8658370

Group type: EXPERIMENTAL
Intervention: Salmeterol 300 micrograms
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Formoterol 72 micrograms
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1380609

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 20 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6151044

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 15

Group type: COMPARATOR
Intervention: Glutethimide (placebo)
Number of subjects: 15
Study: 30836981

Group type: EXPERIMENTAL
Intervention: Continuation of renin-angiotensin system inhibitors (RASi)
Number of subjects: 2222

Group type: COMPARATOR
Intervention: Discontinuation of renin-angiotensin system inhibitors (RASi) 48 hours before surgery
Number of subjects: 2222
Study: 29369904

Group type: EXPERIMENTAL
Intervention: PRP treatment (1.0 × 10 platelets/cm sprayed on wound)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 27
Study: 27553576

Group type: EXPERIMENTAL
Intervention: Sulthiame
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (no treatment mentioned)
Number of subjects: 43
Study: 24429541

Group type: EXPERIMENTAL
Intervention: High-palmitic acid (HPA) diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-palmitic acid and high-oleic acid (HOA) diet
Number of subjects: 18
Study: 22709778

Group type: COMPARATOR
Intervention: Physician's dietary advice (PI group) (n=42)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Physician's dietary advice plus personalized diet management by a registered dietitian (DM group) (n=44)
Number of subjects: 86
Study: 20714165

Group type: EXPERIMENTAL
Intervention: Cystatin C
Number of subjects: 34
Study: 17608755

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg/day) for 36 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 22
Study: 15455827

Group type: EXPERIMENTAL
Intervention: Midwife-led labour care model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midwife-and-doctor group
Number of subjects: 0
Study: 11169006

Group type: EXPERIMENTAL
Intervention: High-flux dialyzer membrane (polyamide)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Low-flux dialyzer membrane (cellulosic/cuprophan)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both high-flux and low-flux dialyzer membranes
Number of subjects: 6
Study: 9699399

Group type: EXPERIMENTAL
Intervention: Orthodontic magnets (test)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Demagnetized magnet (control)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal tissues (no contact with magnets)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control and test sites (both)
Number of subjects: 8
Study: 7978420

Group type: COMPARATOR
Intervention: 0.1 mg/kg droperidol (Group 1, n = 10)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.175 mg/kg droperidol (Group 2, n = 10)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.25 mg/kg droperidol (Group 3, n = 20)
Number of subjects: 40
Study: 2532459

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg
Number of subjects: 169

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg
Number of subjects: 169

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 50 mg
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 169

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 169
Study: 954730

Group type: EXPERIMENTAL
Intervention: Treadmill running at 140 m/min for durations ranging from 0.5 to 20 min
Number of subjects: 30
Study: 31612337

Group type: EXPERIMENTAL
Intervention: Structured Reports (SR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Free Text Reports (FTR)
Number of subjects: 24
Study: 30580672

Group type: EXPERIMENTAL
Intervention: Mirror therapy and treadmill training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo intervention (no mirror visual feedback)
Number of subjects: 30
Study: 26095747

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.197% with adjunct dexmedetomidine 0.3 μg·kg(‐1) (Group LAD)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Plain ropivacaine 0.197% (Group LA)
Number of subjects: 43
Study: 23740321

Group type: EXPERIMENTAL
Intervention: 4% articaine + epinephrine 1:100,000
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4% articaine + epinephrine 1:200,000
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4% articaine + epinephrine 1:300,000
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4% articaine + epinephrine 1:400,000
Number of subjects: 10

Group type: COMPARATOR
Intervention: 4% articaine without epinephrine
Number of subjects: 10
Study: 21733144

Group type: EXPERIMENTAL
Intervention: Weighing
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Household measures
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Digital photographs
Number of subjects: 51
Study: 19446149

Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg with high-fat, high-calcium breakfast
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Eltrombopag 75 mg with low-fat, low-calcium meal
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Eltrombopag 75 mg with high-fat, low-calcium meal
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Eltrombopag 75 mg with antacid containing aluminum hydroxide and magnesium carbonate
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (fasted state)
Number of subjects: 44
Study: 17332105

Group type: EXPERIMENTAL
Intervention: Eccentric exercise program for twelve weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard rehabilitation protocol
Number of subjects: 40
Study: 15247109

Group type: EXPERIMENTAL
Intervention: i.m. ketamine 1 mg kg(‐1) in 2 ml plus epidural normal saline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: epidural ketamine 1 mg kg(‐1) in 10 ml plus i.m. normal saline
Number of subjects: 60

Group type: COMPARATOR
Intervention: epidural normal saline 10 ml plus i.m. normal saline 10 ml
Number of subjects: 60
Study: 11793630

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 257
Study: 9471042

Group type: EXPERIMENTAL
Intervention: Da Capo home flowmeter
Number of subjects: 10

Group type: COMPARATOR
Intervention: Urodyn 1000 flowmeter
Number of subjects: 10
Study: 7604698

Group type: EXPERIMENTAL
Intervention: Boneloc cement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Palacos cement
Number of subjects: 30
Study: 2297507

Group type: EXPERIMENTAL
Intervention: Fresh cultured epithelial allografts
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cryopreserved cultured epithelial allografts
Number of subjects: 20
Study: 314787

Group type: EXPERIMENTAL
Intervention: Distal splenorenal (Warren) shunt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mesocaval shunt
Number of subjects: 0
Study: 31258054

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no kinesio taping)
Number of subjects: 20
Study: 30810382

Group type: EXPERIMENTAL
Intervention: Weekly 50 mg of transdermal testosterone plus daily oral 1 mg estradiol valerate for 8 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Only estrogen for 8 weeks
Number of subjects: 70
Study: 28430890

Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainers (VFRs)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Hawley retainers (HRs)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both retainers (HR and VFR)
Number of subjects: 86
Study: 25783154

Group type: EXPERIMENTAL
Intervention: NCPAP cycling (Group A: cycling between NCPAP of 4 cm and 1 liter per minute (LPM) of nasal prongs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous NCPAP (Group B: continuous NCPAP at 4 cm of H2O)
Number of subjects: 30
Study: 25115430

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 22228446

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg bid)
Number of subjects: 451
Study: 18346869

Group type: EXPERIMENTAL
Intervention: Auditory Anchor
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined Textual/Auditory Anchors
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Textual Anchor
Number of subjects: 40

Group type: COMPARATOR
Intervention: No Anchor
Number of subjects: 40
Study: 17598719

Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 64
Study: 15237706

Group type: EXPERIMENTAL
Intervention: Insulin gene pattern risk scores (summed risk score from two single nucleotide polymorphisms: -23 Hph I; +1127 Pst I)
Number of subjects: 158
Study: 11904741

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of parenteral iron
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intramuscular injections of parenteral iron
Number of subjects: 33
Study: 9559452

Group type: EXPERIMENTAL
Intervention: Circuit weight training (CWT) at 40% 1-RM with 60 seconds rest
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Circuit weight training (CWT) at 40% 1-RM with 30 seconds rest
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Circuit weight training (CWT) at 60% 1-RM with 60 seconds rest
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Circuit weight training (CWT) at 60% 1-RM with 30 seconds rest
Number of subjects: 9

Group type: COMPARATOR
Intervention: Treadmill exercise at 85% of VO2max
Number of subjects: 9
Study: 7655179

Group type: EXPERIMENTAL
Intervention: sCT 100 IU daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: sCT 200 IU daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2744068

Group type: EXPERIMENTAL
Intervention: Witepsol H12 suppositories containing 75 mg, 100 mg, and 150 mg of meptazinol
Number of subjects: 15

Group type: COMPARATOR
Intervention: 200 mg oral tablet of meptazinol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Witepsol H12 suppositories (all doses)
Number of subjects: 15
Study: 76752

Group type: EXPERIMENTAL
Intervention: Acid-phosphatase reaction in T-A.L.L.
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Acid-phosphatase reaction in common-A.L.L.
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Acid-phosphatase reaction in null-A.L.L.
Number of subjects: 148
Study: 30321078

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Number of subjects: 30

Group type: COMPARATOR
Intervention: Microneedling
Number of subjects: 30
Study: 27918916

Group type: EXPERIMENTAL
Intervention: Induced optimism condition (practiced making optimistic future-event predictions)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control condition (viewed stimuli and practiced determining if a phrase contained an adjective)
Number of subjects: 170
Study: 25952257

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 4465

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4465
Study: 22906516

Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg/day, n = 34)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (n = 40)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg/day) in normal DβH level genotype
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg/day) in low DβH level genotype
Number of subjects: 74
Study: 21266648

Group type: EXPERIMENTAL
Intervention: Use of the smartphone with short teleconsultations every 2 weeks (G3)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Home use of a smartphone recommending insulin doses with quarterly visits (G2)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual quarterly follow-up (G1)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Diabeo system (G3)
Number of subjects: 180
Study: 19856688

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.25% bupivacaine (2 mL/h) plus intravenous analgesics
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intravenous analgesics only (control group)
Number of subjects: 26
Study: 17112805

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose
Number of subjects: 60
Study: 16792649

Group type: EXPERIMENTAL
Intervention: New device for nail trephination using mesoscission technology
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: New device for nail trephination
Number of subjects: 14